Venetoclax

Where the papers sit

29 papers from the last 6 months study venetoclax directly · updated from PubMed 12 Oct 2026

• AML Resistance and Combination Therapy

  AML treatment is moving beyond venetoclax plus azacitidine through combinations that target resistance, metabolism, translation, and immune dysfunction. PRMT9-dependent splicing, impaired translation, and oxidative phosphorylation recur as mechanisms that can restore venetoclax sensitivity. Rosuvastatin, PP2A-B56α stabilization, cytarabine, translation inhibitors, and γδ T-cell or CAR-T approaches are being tested to deepen responses. Genomic profiling and ex vivo drug sensitivity are increasingly used to predict remission, relapse, and treatment failure.

  11 papers · 37.9%

• Venetoclax-Based Frontline AML

  Venetoclax plus hypomethylating agents is consolidating as a lower-intensity frontline option for older or unfit patients with AML. Real-world cohorts and nationwide studies focus on composite remission, survival, treatment duration, and comparison with intensive chemotherapy or other regimens. Fixed-time and oral strategies aim to reduce treatment burden while maintaining durable disease control. FLT3-mutated AML remains a key challenge, with gilteritinib combinations addressing relapse risk and molecularly defined resistance.

  7 papers · 24.1%

• BCL2 Inhibition in Blood Cancers

  BCL2 inhibition is moving from proof of target engagement toward approved and combination-based treatment across lymphoid and myeloid cancers. Venetoclax is being paired with obinutuzumab, decitabine, or navitoclax to deepen responses in CLL, mantle cell lymphoma, and advanced myeloid neoplasms. Dose optimization and accelerated ramp-up aim to preserve efficacy while reducing tumor lysis and febrile neutropenia. Biomarker studies and single-cell imaging continue to define which heterogeneous tumors remain dependent on BCL-2.

  6 papers · 20.7%

• High-Risk Hematologic Treatment

  High-risk leukemia and lymphoma are driving venetoclax use in salvage, transplant conditioning, and post-transplant maintenance. Acute myeloid leukemia studies seek a therapeutic window that limits relapse without worsening neutropenia or compromising allogeneic transplantation. Combination strategies extend to ibrutinib in TP53-mutated mantle cell lymphoma and chemo-immunotherapy in Richter transformation. The shared direction is risk-adapted treatment for relapsed or biologically aggressive disease, although optimal sequencing around transplantation remains unsettled.

  5 papers · 17.2%